- Home
- OSPN vs DNTH Comparison
OSPN vs DNTH Comparison
Compare OSPN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSPN
- DNTH
- Stock Information
- Founded
- OSPN 1991
- DNTH 2015
- Country
- OSPN United States
- DNTH United States
- Employees
- OSPN N/A
- DNTH N/A
- Industry
- OSPN EDP Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- OSPN Technology
- DNTH Health Care
- Exchange
- OSPN Nasdaq
- DNTH Nasdaq
- Market Cap
- OSPN 702.8M
- DNTH 565.7M
- IPO Year
- OSPN 1998
- DNTH N/A
- Fundamental
- Price
- OSPN $14.35
- DNTH $19.50
- Analyst Decision
- OSPN Strong Buy
- DNTH Strong Buy
- Analyst Count
- OSPN 4
- DNTH 8
- Target Price
- OSPN $17.63
- DNTH $54.33
- AVG Volume (30 Days)
- OSPN 342.5K
- DNTH 418.5K
- Earning Date
- OSPN 05-01-2025
- DNTH 05-08-2025
- Dividend Yield
- OSPN 0.84%
- DNTH N/A
- EPS Growth
- OSPN N/A
- DNTH N/A
- EPS
- OSPN 1.46
- DNTH N/A
- Revenue
- OSPN $243,179,000.00
- DNTH $6,235,000.00
- Revenue This Year
- OSPN $4.31
- DNTH N/A
- Revenue Next Year
- OSPN $5.31
- DNTH N/A
- P/E Ratio
- OSPN $9.83
- DNTH N/A
- Revenue Growth
- OSPN 3.43
- DNTH 120.63
- 52 Week Low
- OSPN $9.68
- DNTH $13.37
- 52 Week High
- OSPN $20.36
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- OSPN 39.70
- DNTH 53.31
- Support Level
- OSPN $14.26
- DNTH $18.37
- Resistance Level
- OSPN $14.68
- DNTH $19.76
- Average True Range (ATR)
- OSPN 0.72
- DNTH 1.93
- MACD
- OSPN 0.06
- DNTH 0.45
- Stochastic Oscillator
- OSPN 51.82
- DNTH 95.93
About OSPN OneSpan Inc.
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.